Phase II Trial of Lenvatinib in Metastatic or Advanced Pheochromocytoma and Paraganglioma

Trial Profile

Phase II Trial of Lenvatinib in Metastatic or Advanced Pheochromocytoma and Paraganglioma

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 30 May 2017

At a glance

  • Drugs Lenvatinib (Primary)
  • Indications Paraganglioma; Phaeochromocytoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 May 2017 Planned initiation date changed from 1 Apr 2017 to 1 Jul 2017.
    • 06 Mar 2017 Planned initiation date changed from 1 Feb 2017 to 1 Apr 2017.
    • 06 Jan 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top